Last updated: 09/12/2023 06:50:59
An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of VOLIBRIS in Korean subjects in usual practicePMS in PAH
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and effectiveness of VOLIBRIS in Korean subjects in usual practice
Trial description: Ambrisentan (VOLIBRIS; a trademark of Gilead Sciences, Inc,. that GSK uses under license) is used in treatment of Pulmonary Arterial Hypertension (PAH). Ambrisentan has been approved on 20 April 2009 in Korea as an orphan drug for the treatment of PAH to improve exercise ability and delay clinical worsening. Orphan drug designation for Ambrisentan will be revoked and it is to be approved as a new drug in 2015 for the same indication. Therefore post marketing surveillance will be conducted to monitor the safety and effectiveness based on the data collected in Korean subject in a real clinical practice according to PMS regulation. It is an open-label, single arm, multi centre study with a surveillance period planned from 2016 to 2021. About 600 subjects will be recruited for up to 6 years according to PMS regulation. For initial 2 years periodic report every 6 months will be submitted after approving the product as a new drug and later every 1 year for the remaining follow-up years.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Number of subjects having adverse event (AE) and serious adverse event (SAE).
Timeframe: 12 weeks
Secondary outcomes:
Six minutes walk distance (6 MWD) as an evaluation of effectiveness of Ambrisentan
Timeframe: Enrollment and Week 12
World Health Organization (WHO) functional class as an evaluation of effectiveness of Ambrisentan
Timeframe: Enrollment and Week 12
Borg Dyspnea Index (BDI) measurement as an evaluation of effectiveness of Ambrisentan
Timeframe: Enrollment and Week 12
Interventions:
Drug: VOLIBRIS
Enrollment:
600
Observational study model:
Case-Only
Primary completion date:
2021-01-11
Time perspective:
Prospective
Clinical publications:
Kina Jeon, Sang-Bae Yoo, Yoonhee Lee, Eun-Bin Lee, Hyung-Kwan Kim, Hyuk-Jae Chang, Sung-A Chang. Safety and effectiveness of ambrisentan in real clinical practice in pulmonary arterial hypertension: Results from the Korean post-marketing surveillance. Pharmacoepidemiology and drug safety. 2023-Jul-27;
DOI:10.1002/pds.5671
PMID: 37501534
Medical condition
Hypertension, Pulmonary
Product
ambrisentan
Collaborators
Not applicable
Study date(s)
September 2016 to November 2021
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
Not applicable
- Korean subjects with WHO functional class II or III pulmonary arterial hypertension (PAH) (WHO Group 1)
- Subjects at an age of 18 or older who will administer (new users) or are administering (repeated users) VOLIBRIS according to locally approved prescribing information
- Female who is pregnant or has possibility of being pregnant
- Subject who is breast-feeding
Inclusion and exclusion criteria
Inclusion criteria:
- Korean subjects with WHO functional class II or III pulmonary arterial hypertension (PAH) (WHO Group 1)
- Subjects at an age of 18 or older who will administer (new users) or are administering (repeated users) VOLIBRIS according to locally approved prescribing information
Exclusion criteria:
- Female who is pregnant or has possibility of being pregnant
- Subject who is breast-feeding
- Subject with severe hepatic impairment (with and without cirrhosis)
- Subject with aminotransferase (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) > 3 x Upper Limit of Normal (ULN)
- Subject who experienced hypersensitivity to the ingredient.
- Subject with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
- Subject with idiopathic pulmonary fibrosis (IPF) (with and without secondary pulmonary arterial hypertension)
Trial location(s)
No location data available.
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2021-01-11
Actual study completion date
2021-01-11
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Participate in clinical trial
Additional information
Interim CTR Summary
Click hereAccess to clinical trial data by researchers
Visit website